Southeast Asia Antiviral Drug Market growing owing to fueling the need for treatment of viral diseases and increasing immune system
The Southeast Asia antiviral drug market has the potential to grow with propelling CAGR in the forecast period from 2020-2027. The emerging demand for the antiviral drug in Southeast Asia is mainly owing to emerging viral diseases, low immunity systems, the prevalence of hepatitis C and influenza is driving the market share.
With the emergence of anti-hepatitis C drugs and a new generation of anti-AIDS drugs, the market pattern of antiviral medications has quietly changed. The effective antiviral therapies are propelling the treatment of AIDS has improved the life of the patients.
The market value of anti-hepatitis C drugs and anti-AIDS drugs is the main factor driving the growth of the Southeast Asia antiviral drug market. With the advent of new anti-hepatitis C drugs and the birth of new anti-AIDS drugs and multiple anti-AIDS drug compound preparations with different mechanisms of action, the Southeast Asia antiviral drug market will continue to expand.
Moreover, Antiviral drugs can reduce symptoms and shorten the period of illness, just like the role of seasonal flu. These drugs can also help prevent severe disease and death. The mechanism of antiviral drugs is to achieve resistance to further infection of the virus by affecting a specific part of the interference virus replication cycle.
Drug Class overview in the Southeast Asia antiviral drug market
Based on the drug class, the Southeast Asia antiviral drug market segment into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others. The Reverse Transcriptase Inhibitors segment accounted for the largest share in the Southeast Asia antiviral drug market. Reverse Transcriptase Inhibitors is the first drug to fight against the human immunodeficiency virus and treat acquired immune deficiency syndrome (AIDS). The development of nucleotide HIV reverse transcriptase inhibitors (NRTI), non-nucleotide HIV reverse transcriptase inhibitors (NNRTI), HIV protease inhibitors (PI) has sprung up, and the development trend is rapid. The speed ranked as the first ant-viral drugs.
Application overview in the Southeast Asia antiviral drug market
Based on the application, the Southeast Asia antiviral drug market classified into HIV, Hepatitis, Influenza. The Hepatitis segment is estimated to dominates the maximum share of Southeast Asia antiviral drug market in the forecast period. These drugs can slow or stop the hepatitis virus, thereby reducing liver inflammation and damage. Antiviral drugs recommended as they are safer and most effective. Compared with the old antiviral medications, they also have better drug resistance, which means that when they have taken as prescribed, mutations and drug resistance are less likely to occur.
Type overview in the Southeast Asia antiviral drug market
Based on the type, the Southeast Asia antiviral drug bifurcated into Branded, Generic. Branded dominates the largest market share in the Southeast Asia antiviral drug market. It is mainly due to the belief in people that branded drugs help in curing the disease faster than generic. Moreover, branded drugs certified by the government and also prescribed by the doctors. Therefore, the demand for branded medications is higher than generic drugs.
Region overview in the Southeast Asia antiviral drug market
Based on geography, the Southeast Asia antiviral drug market segmented Indonesia, Malaysia, Philippines, Thailand, Vietnam, Singapore, Myanmar, Rest of Southeast Asia. Vietnam region is capturing the largest market share of the Southeast Asia antiviral drug market. It is mainly owing to the awareness among people regarding the viral diseases and availability of antiviral drugs used for the treatment of HIV disease is propelling the market demand for the antiviral drug in Vietnam.
Southeast Asia antiviral drug Market: Competitive Landscape
Companies such as Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories and others are key players in the Southeast Asia antiviral drug market.
Southeast Asia Antiviral Drug Market Report Content 1. Research Strategic Development 1.1. Market Modelling 1.2. Product Analysis 1.3. Market Trend and Economic Factors Analysis 1.4. Market Segmental Analysis 1.5. Geographical Mapping 1.6. Country Wise Segregation 2. Research Methodology 2.1. Identification of Target Market 2.2. Data Acquisition 2.3. Refining of Data/ Data Transformations 2.4. Data Validation through Primary Techniques 2.5. Exploratory Data Analysis 2.6. Graphical Techniques/Analysis 2.7. Quantitative Techniques/Analysis 2.8. Visual Result/Presentation 3. Executive Summary 4. Market Insights 4.1. Supply Chain Analysis 4.2. Economic Factor Analysis 4.2.1. Drivers 4.2.2. Trends 4.2.3. Opportunities 4.2.4. Challenges 4.3. Technological Landscape 4.4. Competitors & Product Analysis 4.5. Export-Import Analysis 4.6. Regulatory Framework 4.7. Company market share analysis, 2019 4.8. Porter's Five forces analysis 4.9. New Investment Analysis 4.10. PESTEL Analysis 5. Southeast Asia Antiviral Drug Market Overview 5.1. Market Size & Forecast, 2016-2027 5.1.1. Demand 5.1.1.1. By Value (USD Billion) 5.2. Market Share & Forecast, 2016-2027 5.2.1. By Drug Class 5.2.1.1. DNA Polymerase Inhibitors 5.2.1.2. Reverse Transcriptase Inhibitors 5.2.1.3. Protease Inhibitors 5.2.1.4. Neuraminidase Inhibitors 5.2.1.5. Others 5.2.2. By Type 5.2.2.1. Branded 5.2.2.2. Generic 5.2.3. By Application 5.2.3.1. HIV 5.2.3.2. Hepatitis 5.2.3.3. Herpes 5.2.3.4. Influenza 5.2.3.5. Others 5.2.4. By Country 5.2.4.1. Indonesia 5.2.4.2. Malaysia 5.2.4.3. Philippines 5.2.4.4. Thailand 5.2.4.5. Vietnam 5.2.4.6. Singapore 5.2.4.7. Myanmar 5.2.4.8. Rest of Southeast Asia 6. Singapore Antiviral Drug Market Overview 6.1. Singapore Antiviral Drug Market Size & Forecast, 2016-2027 6.1.1. Demand 6.1.1.1. By Value (USD Billion) 6.2. Singapore Antiviral Drug Market Share & Forecast, 2016-2027 6.2.1. By Drug Class 6.2.1.1. DNA Polymerase Inhibitors 6.2.1.2. Reverse Transcriptase Inhibitors 6.2.1.3. Protease Inhibitors 6.2.1.4. Neuraminidase Inhibitors 6.2.1.5. Others 6.2.2. By Type 6.2.2.1. Branded 6.2.2.2. Generic 6.2.3. By Application 6.2.3.1. HIV 6.2.3.2. Hepatitis 6.2.3.3. Herpes 6.2.3.4. Influenza 6.2.3.5. Others 6.2.4. Price-Point Analysis 6.2.5. Manufacturer & Distributor List (Top 5) 6.2.6. Company Market Share (Top 3-5) 6.2.7. Economic Impact Study on Singapore Antiviral Drug Market 7. Malaysia Antiviral Drug Market Overview 7.1. Malaysia Antiviral Drug Market Size & Forecast, 2016-2027 7.1.1. Demand 7.1.1.1. By Value (USD Billion) 7.2. Malaysia Antiviral Drug Market Share & Forecast, 2016-2027 7.2.1. By Drug Class 7.2.1.1. DNA Polymerase Inhibitors 7.2.1.2. Reverse Transcriptase Inhibitors 7.2.1.3. Protease Inhibitors 7.2.1.4. Neuraminidase Inhibitors 7.2.1.5. Others 7.2.2. By Type 7.2.2.1. Branded 7.2.2.2. Generic 7.2.3. By Application 7.2.3.1. HIV 7.2.3.2. Hepatitis 7.2.3.3. Herpes 7.2.3.4. Influenza 7.2.3.5. Others 7.2.4. Price-Point Analysis 7.2.5. Manufacturer & Distributor List (Top 5) 7.2.6. Company Market Share (Top 3-5) 7.2.7. Economic Impact Study on Malaysia Antiviral Drug Market 8. Vietnam Antiviral Drug Market Overview 8.1. Vietnam Antiviral Drug Market Size & Forecast, 2016-2027 8.1.1. Demand 8.1.1.1. By Value (USD Billion) 8.2. Vietnam Antiviral Drug Market Share & Forecast, 2016-2027 8.2.1. By Drug Class 8.2.1.1. DNA Polymerase Inhibitors 8.2.1.2. Reverse Transcriptase Inhibitors 8.2.1.3. Protease Inhibitors 8.2.1.4. Neuraminidase Inhibitors 8.2.1.5. Others 8.2.2. By Type 8.2.2.1. Branded 8.2.2.2. Generic 8.2.3. By Application 8.2.3.1. HIV 8.2.3.2. Hepatitis 8.2.3.3. Herpes 8.2.3.4. Influenza 8.2.3.5. Others 8.2.4. Price-Point Analysis 8.2.5. Manufacturer & Distributor List (Top 5) 8.2.6. Company Market Share (Top 3-5) 8.2.7. Economic Impact Study on Vietnam Antiviral Drug Market 9. Indonesia Antiviral Drug Market Overview 9.1. Indonesia Antiviral Drug Market Size & Forecast, 2016-2027 9.1.1. Demand 9.1.1.1. By Value (USD Billion) 9.2. Indonesia Antiviral Drug Market Share & Forecast, 2016-2027 9.2.1. By Drug Class 9.2.1.1. DNA Polymerase Inhibitors 9.2.1.2. Reverse Transcriptase Inhibitors 9.2.1.3. Protease Inhibitors 9.2.1.4. Neuraminidase Inhibitors 9.2.1.5. Others 9.2.2. By Type 9.2.2.1. Branded 9.2.2.2. Generic 9.2.3. By Application 9.2.3.1. HIV 9.2.3.2. Hepatitis 9.2.3.3. Herpes 9.2.3.4. Influenza 9.2.3.5. Others 9.2.4. Price-Point Analysis 9.2.5. Manufacturer & Distributor List (Top 5) 9.2.6. Company Market Share (Top 3-5) 9.2.7. Economic Impact Study on Indonesia Antiviral Drug Market 10. Thailand Antiviral Drug Market Overview 10.1. Thailand Antiviral Drug Market Size & Forecast, 2016-2027 10.1.1. Demand 10.1.1.1. By Value (USD Billion) 10.2. Thailand Antiviral Drug Market Share & Forecast, 2016-2027 10.2.1. By Drug Class 10.2.1.1. DNA Polymerase Inhibitors 10.2.1.2. Reverse Transcriptase Inhibitors 10.2.1.3. Protease Inhibitors 10.2.1.4. Neuraminidase Inhibitors 10.2.1.5. Others 10.2.2. By Type 10.2.2.1. Branded 10.2.2.2. Generic 10.2.3. By Application 10.2.3.1. HIV 10.2.3.2. Hepatitis 10.2.3.3. Herpes 10.2.3.4. Influenza 10.2.3.5. Others 10.2.4. Price-Point Analysis 10.2.5. Manufacturer & Distributor List (Top 5) 10.2.6. Company Market Share (Top 3-5) 10.2.7. Economic Impact Study on Thailand Antiviral Drug Market 11. Rest of Southeast Asia Antiviral Drug Market Overview 11.1. Rest of Southeast Antiviral Drug Market Size & Forecast, 2016-2027 11.1.1. Demand 11.1.1.1. By Value (USD Billion) 11.2. Rest of Southeast Asia Antiviral Drug Market Share & Forecast, 2016-2027 11.2.1. By Drug Class 11.2.1.1. DNA Polymerase Inhibitors 11.2.1.2. Reverse Transcriptase Inhibitors 11.2.1.3. Protease Inhibitors 11.2.1.4. Neuraminidase Inhibitors 11.2.1.5. Others 11.2.2. By Type 11.2.2.1. Branded 11.2.2.2. Generic 11.2.3. By Application 11.2.3.1. HIV 11.2.3.2. Hepatitis 11.2.3.3. Herpes 11.2.3.4. Influenza 11.2.3.5. Others 11.2.4. By Country 11.2.4.1. Philippines 11.2.4.2. Myanmar 11.2.4.3. Brunei 11.2.4.4. Cambodia 11.2.4.5. Laos 11.2.5. Price-Point Analysis 11.2.6. Manufacturer & Distributor List (Top 5) 11.2.7. Company Market Share (Top 3-5) 11.2.8. Economic Impact Study on Rest of Southeast Asia Antiviral Drug Market 12. Competitor Analysis 12.1. Company Description 12.2. Financial Analysis 12.3. Key Products 12.4. Key Management Personnel 12.5. Contact Address 12.6. SWOT Analysis 12.7. Company Profile 12.7.1. Gilead sciences 12.7.2. F. Hoffmann-La Roche AG 12.7.3. GlaxoSmithKline plc 12.7.4. AbbVie 12.7.5. Merck & Co., Inc. 12.7.6. Johnson & Johnson Services, Inc. 12.7.7. Bristol-Myers Squibb Company 12.7.8. Cipla Inc. 12.7.9. Aurobindo Pharma 12.7.10. Dr. Reddy's Laboratories 12.7.11. Other Prominent Players
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Medical Devices | Pages : 121 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 130 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 119 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 121 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 139 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
